243 related articles for article (PubMed ID: 27386169)
1. Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial).
Stewart Coats AJ; Ho GF; Prabhash K; von Haehling S; Tilson J; Brown R; Beadle J; Anker SD;
J Cachexia Sarcopenia Muscle; 2016 Jun; 7(3):355-65. PubMed ID: 27386169
[TBL] [Abstract][Full Text] [Related]
2. The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design.
Stewart Coats AJ; Srinivasan V; Surendran J; Chiramana H; Vangipuram SR; Bhatt NN; Jain M; Shah S; Ali IA; Fuang HG; Hassan MZ; Beadle J; Tilson J; Kirwan BA; Anker SD;
J Cachexia Sarcopenia Muscle; 2011 Dec; 2(4):201-207. PubMed ID: 22207908
[TBL] [Abstract][Full Text] [Related]
3. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).
Katakami N; Uchino J; Yokoyama T; Naito T; Kondo M; Yamada K; Kitajima H; Yoshimori K; Sato K; Saito H; Aoe K; Tsuji T; Takiguchi Y; Takayama K; Komura N; Takiguchi T; Eguchi K
Cancer; 2018 Feb; 124(3):606-616. PubMed ID: 29205286
[TBL] [Abstract][Full Text] [Related]
4. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.
Temel JS; Abernethy AP; Currow DC; Friend J; Duus EM; Yan Y; Fearon KC
Lancet Oncol; 2016 Apr; 17(4):519-531. PubMed ID: 26906526
[TBL] [Abstract][Full Text] [Related]
5. ACT-ONE - ACTION at last on cancer cachexia by adapting a novel action beta-blocker.
Lainscak M; Laviano A
J Cachexia Sarcopenia Muscle; 2016 Sep; 7(4):400-2. PubMed ID: 27625919
[TBL] [Abstract][Full Text] [Related]
6. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.
Garcia JM; Boccia RV; Graham CD; Yan Y; Duus EM; Allen S; Friend J
Lancet Oncol; 2015 Jan; 16(1):108-16. PubMed ID: 25524795
[TBL] [Abstract][Full Text] [Related]
7. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.
Takayama K; Katakami N; Yokoyama T; Atagi S; Yoshimori K; Kagamu H; Saito H; Takiguchi Y; Aoe K; Koyama A; Komura N; Eguchi K
Support Care Cancer; 2016 Aug; 24(8):3495-505. PubMed ID: 27005463
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats.
Pötsch MS; Tschirner A; Palus S; von Haehling S; Doehner W; Beadle J; Coats AJ; Anker SD; Springer J
J Cachexia Sarcopenia Muscle; 2014 Jun; 5(2):149-58. PubMed ID: 24272787
[TBL] [Abstract][Full Text] [Related]
10. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia.
Currow D; Temel JS; Abernethy A; Milanowski J; Friend J; Fearon KC
Ann Oncol; 2017 Aug; 28(8):1949-1956. PubMed ID: 28472437
[TBL] [Abstract][Full Text] [Related]
11. A Double-Blind, Placebo-Controlled Randomized Phase IIa Study: Evaluating the Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Solid Cancer Patients.
Chaiworramukkul A; Seetalarom K; Saichamchan S; Prasongsook N
Asian Pac J Cancer Prev; 2022 Jul; 23(7):2333-2340. PubMed ID: 35901339
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
13. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
Crawford J; Prado CM; Johnston MA; Gralla RJ; Taylor RP; Hancock ML; Dalton JT
Curr Oncol Rep; 2016 Jun; 18(6):37. PubMed ID: 27138015
[TBL] [Abstract][Full Text] [Related]
14. A triple-masked, two-center, randomized parallel clinical trial to assess the superiority of eight weeks of grape seed flour supplementation against placebo for weight loss attenuation during perioperative period in patients with cachexia associated with colorectal cancer: a study protocol.
Malta FAPS; Gonçalves DC
Front Endocrinol (Lausanne); 2023; 14():1146479. PubMed ID: 38313843
[TBL] [Abstract][Full Text] [Related]
15. Mirtazapine in Cancer-Associated Anorexia and Cachexia: A Double-Blind Placebo-Controlled Randomized Trial.
Hunter CN; Abdel-Aal HH; Elsherief WA; Farag DE; Riad NM; Alsirafy SA
J Pain Symptom Manage; 2021 Dec; 62(6):1207-1215. PubMed ID: 34051293
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide Celgene Corp.
Bruyn GA
IDrugs; 1998 Aug; 1(4):490-500. PubMed ID: 18465584
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Curcumin on Treating Cancer Anorexia-Cachexia Syndrome in Locally or Advanced Head and Neck Cancer: A Double-Blind, Placebo-Controlled Randomised Phase IIa Trial (CurChexia).
Thambamroong T; Seetalarom K; Saichaemchan S; Pumsutas Y; Prasongsook N
J Nutr Metab; 2022; 2022():5425619. PubMed ID: 35694030
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl beta-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122).
Berk L; James J; Schwartz A; Hug E; Mahadevan A; Samuels M; Kachnic L;
Support Care Cancer; 2008 Oct; 16(10):1179-88. PubMed ID: 18293016
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
